27th Oct 2014 10:16
LONDON (Alliance News) - Physiomic PLC Monday said it has signed an extension project with a "major global" pharmaceutical company.
The UK-based systems biology company said the extension to the Virtual Tumour project will cover predicting optimal regimens for a further candidate compound, which it said should be completed by the end of 2014.
It sad the project will be performed on a fee-for-service basis.
"The fact that the project has been ongoing since 2012 demonstrates the trust that our pharma partner now has in the predictive power of our Virtual Tumour technology", it said.
Physiomics shares were up 2.4% at 0.128 pence Monday morning.
By Rowena Harris-Doughty; [email protected]; @rharrisdoughty
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Physiomics